Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

Biogen stock rises as Novo Nordisk's Alzheimer's trials disappoint, spotlighting Leqembi's role and a new immunology collaboration with Dayra Therapeutics.

New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for ...

The U.S. Food and Drug Administration (FDA) stated on Thursday that it is requiring an additional MRI scan for Alzheimer's patients receiving Leqembi (lecanemab), citing safety concerns over a rare ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06. The company ...

Paul Edison, MD, PhD, of Imperial College London, who wasn't involved with the studies, called the findings "an undeniable ...

Eisai Co. and Biogen Inc. received US regulatory approval for a new self-injected form of their Alzheimer’s drug Leqembi, in a move that could make a complicated treatment regimen more convenient for ...

UnitedHealth Group CEO Andrew Witty said the payer needs to see more data on Aduhelm, Biogen’s controversial Alzheimer’s drug, before it will cover it. During UnitedHealth’s July 15 earnings ...

The Alzheimer’s drugs market is projected to grow at a compound annual growth rate (CAGR) of approximately 20% during the ...